These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19536351)

  • 1. Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.
    Blasi ER; Heyen J; Hemkens M; McHarg A; Ecelbarger CM; Tiwari S
    PPAR Res; 2009; 2009():237865. PubMed ID: 19536351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.
    Tiwari S; Blasi ER; Heyen JR; McHarg AD; Ecelbarger CM
    Pharmacol Res; 2008 May; 57(5):383-92. PubMed ID: 18468451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats.
    Song J; Knepper MA; Hu X; Verbalis JG; Ecelbarger CA
    J Pharmacol Exp Ther; 2004 Feb; 308(2):426-33. PubMed ID: 14593089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.
    Wang X; Liu X; Zhan Y; Lavallie ER; Diblasio-Smith L; Collins-Racie L; Mounts WM; Rutkowski JL; Xu X; Goltsman I; Abassi Z; Winaver J; Feuerstein GZ
    J Pharmacol Exp Ther; 2010 Sep; 334(3):820-9. PubMed ID: 20519551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes.
    Lee TI; Kao YH; Chen YC; Pan NH; Lin YK; Chen YJ
    Clin Sci (Lond); 2011 Oct; 121(7):305-12. PubMed ID: 21501116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure.
    Goltsman I; Wang X; Lavallie ER; Diblasio-Smith EA; Ovcharenko E; Hoffman A; Abassi Z; Feuerstein GZ; Winaver J
    Circ Heart Fail; 2011 May; 4(3):345-54. PubMed ID: 21398416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.
    Khan O; Riazi S; Hu X; Song J; Wade JB; Ecelbarger CA
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F442-50. PubMed ID: 15814531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure.
    Goltsman I; Khoury EE; Aronson D; Nativ O; Feuerstein GZ; Winaver J; Abassi Z
    J Cell Mol Med; 2019 Jul; 23(7):4779-4794. PubMed ID: 31087547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-γ agonist rosiglitazone reverses perinatal nicotine exposure-induced asthma in rat offspring.
    Liu J; Sakurai R; Rehan VK
    Am J Physiol Lung Cell Mol Physiol; 2015 Apr; 308(8):L788-96. PubMed ID: 25659902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice.
    Morrison A; Yan X; Tong C; Li J
    Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H895-902. PubMed ID: 21666107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma.
    Bo QF; Sun XM; Liu J; Sui XM; Li GX
    Oncol Lett; 2015 Oct; 10(4):1979-1984. PubMed ID: 26622783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis.
    Hassumi MY; Silva-Filho VJ; Campos-Júnior JC; Vieira SM; Cunha FQ; Alves PM; Alves JB; Kawai T; Gonçalves RB; Napimoga MH
    Int Immunopharmacol; 2009 Sep; 9(10):1150-8. PubMed ID: 19508902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat.
    Riazi S; Khan O; Tiwari S; Hu X; Ecelbarger CA
    Am J Nephrol; 2006; 26(3):245-57. PubMed ID: 16757903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model.
    Wang Y; Santos J; Sakurai R; Shin E; Cerny L; Torday JS; Rehan VK
    Pediatr Res; 2009 Feb; 65(2):150-5. PubMed ID: 19262292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
    Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
    Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
    Yu X; Li C; Li X; Cai L
    Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protective effects of rosiglitazone on hepatic ischemia reperfusion injury in rats].
    Chen J; Liu H; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):732-737. PubMed ID: 30124208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice.
    Sottili M; Mangoni M; Gerini C; Salvatore G; Castiglione F; Desideri I; Bonomo P; Meattini I; Greto D; Loi M; Francolini G; Perna M; Grassi R; Biti G; Livi L
    Head Neck; 2018 Mar; 40(3):577-583. PubMed ID: 29155481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
    Linz W; Wohlfart P; Baader M; Breitschopf K; Falk E; Schäfer HL; Gerl M; Kramer W; Rütten H
    Acta Pharmacol Sin; 2009 Jul; 30(7):935-46. PubMed ID: 19503102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.